{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:25:04Z","timestamp":1777566304625,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIH","award":["CA022443"],"award-info":[{"award-number":["CA022443"]}]},{"name":"NIH","award":["AI071947"],"award-info":[{"award-number":["AI071947"]}]},{"name":"NIH","award":["AI091968"],"award-info":[{"award-number":["AI091968"]}]},{"DOI":"10.13039\/100009141","name":"Cancer League of Colorado","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009141","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.antiviral.2011.12.007","type":"journal-article","created":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T16:40:26Z","timestamp":1324053626000},"page":"280-287","source":"Crossref","is-referenced-by-count":8,"title":["Novel antivirals inhibit early steps in HPV infection"],"prefix":"10.1016","volume":"93","author":[{"given":"Hao-Shun","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dohun","family":"Pyeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane M.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon M.","family":"Lank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Ahlquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul F.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2011.12.007_b0005","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Abdool Karim","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2011.12.007_b0010","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1093\/annonc\/mdr015","article-title":"Worldwide burden of cervical cancer in 2008","volume":"22","author":"Arbyn","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.antiviral.2011.12.007_b0020","doi-asserted-by":"crossref","unstructured":"Buck, C.B., Thompson, C.D., 2007. Production of papillomavirus-based gene transfer vectors. Curr. Protoc. Cell. Biol., Chapter 26, Unit 26 21.","DOI":"10.1002\/0471143030.cb2601s37"},{"key":"10.1016\/j.antiviral.2011.12.007_b0015","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1128\/JVI.78.2.751-757.2004","article-title":"Efficient intracellular assembly of papillomaviral vectors","volume":"78","author":"Buck","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.12.007_b0025","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1128\/JVI.79.5.2839-2846.2005","article-title":"Maturation of papillomavirus capsids","volume":"79","author":"Buck","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.12.007_b0030","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1371\/journal.ppat.0020069","article-title":"Carrageenan is a potent inhibitor of papillomavirus infection","volume":"2","author":"Buck","year":"2006","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2011.12.007_b0035","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/00007435-199904001-00002","article-title":"Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel","volume":"26","author":"Cates","year":"1999","journal-title":"Sex. Transm. Dis."},{"key":"10.1016\/j.antiviral.2011.12.007_b0040","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1470-2045(05)70086-3","article-title":"Carcinogenicity of human papillomaviruses","volume":"6","author":"Cogliano","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.antiviral.2011.12.007_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0042-6822(02)00143-5","article-title":"Papillomaviruses infect cells via a clathrin-dependent pathway","volume":"307","author":"Day","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2011.12.007_b0050","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1006\/viro.1999.9868","article-title":"Establishment of the human papillomavirus type 16 (HPV-16) life cycle in an immortalized human foreskin keratinocyte cell line","volume":"262","author":"Flores","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2011.12.007_b0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev-immunol-031210-101308","article-title":"Prevention and treatment of papillomavirus-related cancers through immunization","volume":"29","author":"Frazer","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2011.12.007_b0060","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2011.12.007_b0065","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.2174\/138161205774580633","article-title":"Microbicides for prevention of transmission of sexually transmitted diseases","volume":"11","author":"Howett","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.antiviral.2011.12.007_b0070","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.virol.2010.09.002","article-title":"Inhibition of gamma secretase blocks HPV infection","volume":"407","author":"Huang","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2011.12.007_b0075","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1128\/JVI.01081-10","article-title":"Papillomavirus infection requires gamma secretase","volume":"84","author":"Karanam","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.12.007_b0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9343(97)00177-0","article-title":"Epidemiology of genital human papillomavirus infection","volume":"102","author":"Koutsky","year":"1997","journal-title":"Am. J. Med."},{"key":"10.1016\/j.antiviral.2011.12.007_b0085","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1128\/JVI.69.2.948-954.1995","article-title":"Papillomavirus capsid binding and uptake by cells from different tissues and species","volume":"69","author":"M\u00fcller","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.12.007_b0090","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2011.12.007_b0095","doi-asserted-by":"crossref","first-page":"9311","DOI":"10.1073\/pnas.0504020102","article-title":"Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation","volume":"102","author":"Pyeon","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2011.12.007_b0100","doi-asserted-by":"crossref","first-page":"e1000318","DOI":"10.1371\/journal.ppat.1000318","article-title":"Establishment of human papillomavirus infection requires cell cycle progression","volume":"5","author":"Pyeon","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2011.12.007_b0105","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nm1598","article-title":"Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan","volume":"13","author":"Roberts","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2011.12.007_b0110","first-page":"365","article-title":"Primer3 on the WWW for general users and for biologist programmers","volume":"132","author":"Rozen","year":"2000","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.antiviral.2011.12.007_b0115","doi-asserted-by":"crossref","first-page":"9922","DOI":"10.1128\/JVI.00988-07","article-title":"Human papillomavirus type 31 uses a caveolin 1- and dynamin 2-mediated entry pathway for infection of human keratinocytes","volume":"81","author":"Smith","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.12.007_b0120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.antiviral.2011.12.007_b0125","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2008.11.046","article-title":"Papillomaviruses in the causation of human cancers \u2013 a brief historical account","volume":"384","author":"Zur Hausen","year":"2009","journal-title":"Virology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211005262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211005262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T22:55:02Z","timestamp":1593384902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354211005262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0166354211005262"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2011.12.007","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}